Cambridge, UK, 4th September, 2024 – CellCentric, a clinical stage biotechnology company, today announces the appointment of Andy Fergus as Chief Development Officer. Andy brings over 20 years of experience in multiple myeloma drug development. He will help to lead the clinical development of inobrodib, focusing on the current phase II trials and subsequent pivotal studies.
Andy joins CellCentric from Takeda Pharmaceuticals, where he served as Executive Director and Global Project Leader for their Oncology Therapeutic Area, specifically focused on multiple myeloma. At Takeda, he led cross-functional teams through clinical development to regulatory approval and commercialisation. During this time, he made significant contributions to several life-changing therapies for patients with multiple myeloma.
Will West, CEO of CellCentric commented: “Andy brings important and extensive experience to the team at this critical time in the development of inobrodib. We welcome his energy and insights as we continue to move towards our goal of delivering a high impact treatment for cancer that reaches the widest communities.”
Andy Fergus said: “I have a deep commitment to improving and extending the lives of people with multiple myeloma. I am thrilled for this next step in my career where I can continue to progress advancements of much needed agents with novel mechanisms of action that are also easy-to-administer. Inobrodib has demonstrated very encouraging clinical data to date, and I look forward to being part of the outstanding leadership team at CellCentric to bring this novel treatment to patients in need.”
CellCentric recently secured a $35 million investment from RA Capital Management, which will be used to complete development activities in alignment with FDA requirements, to ensure full readiness for pivotal clinical trials.
About inobrodib
Inobrodib is a new type of treatment for people with cancer. Delivered as an oral capsule, it is easy for patients to take and can be used at home without the need for intensive monitoring. As it has a good safety profile for a drug in this setting, it may be used by those who are unable to access or tolerate other types of treatment. It has the potential to present a lower overall burden on the healthcare system as compared to more complex agents.
About CellCentric
CellCentric is an innovative UK-based biotechnology company with offices in Cambridge and Manchester. The company was spun out from the University of Cambridge by pioneering developmental biologist Professor Azim Surani FRS, CBE, who wanted to further explore the potential of targeting cell fate control mechanisms. From its origins, CellCentric built a network of research and evaluation relationships with over 25 leading academic research groups worldwide. CellCentric’s research evolved to focus on twin transcription co-activation factors, p300 and CBP, that drive the expression of genes important in cancer progression. The company actively pursued multiple cell fate control-related drug discovery programmes before focusing on p300/CBP inhibition and inobrodib.
